(Q34636674)

3 August 2017

1 reference

title

Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder (English)

1 reference

post-traumatic stress disorder

3 August 2017

0 references

author name string

Chi-Un Pae

1

1 reference

3 August 2017

Hyun-Kook Lim

2

1 reference

3 August 2017

Neena Ajwani

3

1 reference

3 August 2017

Chul Lee

4

1 reference

3 August 2017

Ashwin A Patkar

5

1 reference

3 August 2017

1 June 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

3 August 2017

1 reference

3 August 2017

7

1 reference

3 August 2017

603-615

1 reference

3 August 2017

6

1 reference

SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Posttraumatic stress disorder in the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Posttraumatic stress disorder in the primary care medical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Posttraumatic stress disorder in primary care: prevalence and relationships with physical symptoms and medical utilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Mental health treatment received by primary care patients with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Quality of care for primary care patients with anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Predicting posttraumatic stress symptoms from pretraumatic risk factors: a 2-year prospective follow-up study in firefighters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Post-traumatic stress disorder and other co-morbidities in a sample population of patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Hypodensity of platelet serotonin uptake sites in posttraumatic stress disorder: associated clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Serotonergic and noradrenergic markers of post-traumatic stress disorder with and without major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Venlafaxine: a 2003 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

The treatment of depression with different formulations of venlafaxine: a comparative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Time course of clinical response to venlafaxine: relevance of plasma level and chirality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

New formulations of existing antidepressants: advantages in the management of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Characterizing the effects of sertraline in post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Paroxetine: current status in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Post-traumatic stress disorder and somatization symptoms: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.603

21 January 2018

Identifiers

DOI

10.1586/14737175.7.6.603

1 reference

3 August 2017

1 reference